A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J. et al, (2022), Blood, 139, 2931 - 2941
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.
Li L. et al, (2022), Blood, 139, 2797 - 2815
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.
Lim SH. et al, (2022), Nat Cancer, 3, 552 - 564
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Telli ML. et al, (2022), NPJ Breast Cancer, 8
Exploratory Analysis: Potential of pelabresib (CPI-0610), a bromodomain and extra-terminal domain inhibitor, as suggested by analysis of improvements in bone marrow histology and function in patients with myelofibrosis-preliminary data
Harrison C. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 27 - 28
Longitudinal and Individual Symptom Analyses of Momelotinib and Ruxolitinib-Treated Myelofibrosis Patients from SIMPLIFY-1
Mesa R. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 79 - 80
Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis-update of clinical and translational data from the ongoing MANIFEST trial
Curto-Garcia N. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 75 - 76
Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study.
Clift AK. et al, (2022), BMJ Open, 12
Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.
Pantziarka P. and Blagden S., (2022), Cancers (Basel), 14
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer
Fletcher CE. et al, (2022), Molecular Cancer, 21, 82 - 82
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58
Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging.
Scott NP. et al, (2022), Br J Cancer, 126, 598 - 605
The current status of risk-stratified breast screening.
Clift AK. et al, (2022), Br J Cancer, 126, 533 - 550
The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.
Strickland M. et al, (2022), Br J Haematol, 196, 1149 - 1158
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.
van Vugt MATM. and Parkes EE., (2022), Trends Cancer, 8, 174 - 189
Targeting MAPK in recurrent, low-grade serous ovarian cancer.
Blagden SP., (2022), Lancet, 399, 499 - 501
Targeting OXPHOS and the electronic transport chain in cancer; Molecular and therapeutic implications.
Greene J. et al, (2022), Semin Cancer Biol
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
Parkes EE. et al, (2022), Br J Cancer, 126, 247 - 258
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Long GV. et al, (2022), Ann Oncol, 33, 204 - 215